

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ART UNIT:

Daphne Miller

1642

EXAMINER: David J. Blanchard

pplication of

: Subhashis Banerjee et al.

Serial No.

: 10/623,065

Filed

: July 18, 2003

Entitled

: TREATMENT OF CORONARY

DISORDERS USING TNFα

INHIBITORS

Attorney Docket No. BBC-202

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated

date of mailing and signature

TRANSMITTAL LETTER

Sir/Madam:

(L

Transmitted herewith are: [X] Change of Attorney Docket Number and Change of Correspondence Address; [X] An Information Disclosure Statement under 37 CFR §§ 1.56, 1.97 and 1.98; [X] Form PTO-1449 Information Disclosure Statement; [X] A photocopy of each reference cited; and [X] An Acknowledgement Postcard; to be filed in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS

A fee for additional claims is not required. [X]

A fee for additional claims is required. The additional fee has been calculated as shown below:

	CLAIMS REMAINING AFTER	HIGHEST NUMBER PREVIOUSLY	NUMBER OF EXCESS CLAIMS	RATE		FEES DUE	
TOTAL CLAIMS	AMENDMENT	PAID FOR 38	0	×\$18	=	0.00	
INDEPENDENT		13	0	× \$84	=	0.00	\neg
FIRST INTRODUCTION OF MULT. DEPENDENT CLAIM +\$280						0.00	
TOTAL FEES DUE						00.00	

PETITION FOR EXTENSION OF TIME

[]	Extension is requested under 37 CFR 1.136(a), and the following extension fee is applicable for the
		paper(s) filed herewith: [] \$110.00 for response within first month pursuant to 37 CFR 1.17(a)(1);
		[] \$430.00 for response within second month pursuant to 37 CFR 1.17(a)(2);
		[] \$980.00 for response within third month pursuant to 37 CFR 1.17(a)(3);
		[] \$1,530.00 for response within fourth month pursuant to 37 CFR 1.17(a)(4).
		[] \$2,080.00 for response within fifth month pursuant to 37 CFR 1.17(a)(5).

[X] The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to **Deposit Account No.**010025. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

Tara Seshadri, Ph.D. Agent for Applicant Registration No. 48,591 Abbott Bioresearch Center 100 Research Drive

Worcester, MA 01605-4314 Telephone: (508) 688-8058 Telefax: (508) 688-8110

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ART UNIT: 1642

EXAMINER: David J. Blanchard

Daphne Miller

pplication of:

Subhashis Banerjee et al.

Serial No.:

10/623,065

Filed:

July 18, 2003

Entitled:

TREATMENT OF CORONARY

DISORDERS USING TNFa

INHIBITORS

Attorney Docket No.: BBC-202

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Change of Attorney Docket Number and Change of Correspondence Address (37 CFR 1.8(a))

Sir/Madam:

Please note that the Attorney Docket No. for the above-identified application has been changed from BPI-190 to BBC-202.

Please send all correspondence relating to the above patent application to:

Tara Seshadri Abbott Bioresearch Center 100 Research Drive Worcester, MA 01605

Respectfully submitted,

Tara Seshadri, Ph.D. Agent for Applicant Registration No. 48,591

Abbott Bioresearch Center, Inc.

100 Research Drive

Worcester, MA 01605-4314 Telephone: (508) 688-8058

Telefax: (508) 688-8110